Download presentation
Presentation is loading. Please wait.
Published byBrianne Garrett Modified over 6 years ago
1
[68Ga]Pentixafor PET/CT and [18F]FDG PET/CT A–DMaximum intensity projections (MIP) of [68Ga]Pentixafor (A) and [18F]FDG PET/CT (B) of a 68‐year‐old male with histologically proven multiple myeloma indicating the better lesion‐to‐background contrast for [68Ga]Pentixafor in the corresponding myeloma manifestations. [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT A–DMaximum intensity projections (MIP) of [68Ga]Pentixafor (A) and [18F]FDG PET/CT (B) of a 68‐year‐old male with histologically proven multiple myeloma indicating the better lesion‐to‐background contrast for [68Ga]Pentixafor in the corresponding myeloma manifestations. Trans‐axial views of the upper thorax (C) and the pelvis (D) underline the higher uptake values of the bone manifestations (yellow arrows) of [68Ga]Pentixafor compared to [18F]FDG. Kathrin Philipp‐Abbrederis et al. EMBO Mol Med. 2015;emmm © as stated in the article, figure or figure legend
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.